jump there. Now, we've got more news on Astroenica. We were talking about this a few days ago.Angelica Peeles has the details for us. Hi, Angelica. Hey there.That's right. So, Bloomberg is reporting that Astroenica is in talks with Summit Therapeutics to license the company's experimental lung cancer drug for up to $15 billion. Now, Bloomberg is attributing this to people familiar with the matter.Now, this has been an incredibly hot area of development. Summit has really um shephered this whole field. this ...

AstraZeneca is discussing a partnership deal with Summit Therapeutics in which it could pay as much as $15 billion over time to license a lung-cancer drug https://t.co/QRsUkHJHsQ ...

According to a report in The Times, AstraZeneca's boss is considering moving the company's listing and domicile to the US. Given that the drugs maker is one of the UK's top listed firms, what would it mean for a beleaguered London market? https://t.co/7XSx1qWWh7 ...

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca’s CEO wants to move the company’s listing to the US https://t.co/nErLNjfqGk ...

Astrazeneca (AZN) closed the most recent trading day at $71.46, moving +2.26% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. Elsewhere, the Dow saw an upswing of 0.91%, while the tech-heavy Nasdaq depreciated by 0.82%. Shares of the pharmaceutical have depreciated by 2.85% over the course of the past month, underperforming the Medical sector's gain of 1.66%, and the S&P 500's gain of 5.17%.Investors will be eagerly watching for the performance of A ...

Trading in AstraZeneca's (AZN 2.26%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session. With that rise, it did better than the S&P 500 (^GSPC -0.11%), which closed the day marginally (0.1%) lower.Bye-bye Britain?That morning, U.K. newspaper The Times published an article stating that AstraZeneca CEO Pascal Soriot aims to ...

据泰晤士报：阿斯利康首席执行官已讨论将上市地点迁往美国。 ...

阿斯利康CEO据悉已经讨论将上市地迁往美国的可能性。 ...

智通财经7月1日电，阿斯利康CEO据悉已经讨论将上市地迁往美国的可能性。 ...

When I last wrote about the oncology focused company, AstraZeneca (NASDAQ: AZN ) in November, a Buy rating appeared contrarian. Following a fraud investigation in China, its price saw a sharp fall. And with no way of knowing when the matter would be resolved, it Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green ...